Abstract and Introduction
Systemic hypertension is a common condition that substantially increases the risk of cardiovascular events. Despite this, blood pressure (BP) control with pharmacological antihypertensive therapy remains challenging and control rates are well below the optimal level. This common unmet need meant that mechanical approaches to treat hypertension were enthusiastically received. As a result, the development and potential utility of renal denervation (RDN) to treat hypertension, especially resistant hypertension, was welcomed as a 'spectacular' breakthrough in modern therapeutics. It seemed that the unmet need in hypertension might finally be fulfilled. Clinical research in RDN advanced at a 'hasty' speed, perhaps now recently matched by the rapid development of a vaccine against the SARS-CoV-2 virus. However, the enthusiasm for this mechanical marvel subsided as quickly as it developed.
Eur Heart J. 2022;43(23):2177-2178. © 2022 Oxford University Press
Copyright 2007 European Society of Cardiology. Published by Oxford University Press. All rights reserved.